About CTI BioPharma
CTI BioPharma is a Healthcare company based in Seattle (United States) founded in 1991, and was acquired by Swedish Orphan Biovitrum in May 2023. Targeted small molecule therapeutics for blood cancers are developed. The company has 25 employees. CTI BioPharma has completed 1 acquisition, including Zhejiang Novus Pharmaceuticals. CTI BioPharma offers products and services including Haematology Treatments, Immunology Treatments, and Specialty Care Medicines. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is CTI BIOPHARMA CORP. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Developer of targeted small molecule therapeutics for blood cancer. Their flagship product Pixantrone was granted conditional marketing approval in the EU, as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphomas. Other drugs in the pipeline are Pacritinib (myelofibrosis and relapsed acute myeloid leukemia), Tosedostat (relapsed acute myeloid leukemia and myelodysplastic syndrome), and Paclitaxel poliglumex (ovarian cancer).
- Headquarters Seattle, United States
- Employees 25
- Stage Acquired
- SectorsHealthcare
- Website ctibiopharma.com
- Social LinkedIn X
- Acquired by Swedish Orphan Biovitrum (May 2023)
- Legal Name Cti Biopharma Corp
- Latest Funding Round$45M (USD), Post-IPO
Jun 2017
- InvestorsSwedish Orphan Biovitrum
& 2 more
- Employee Count25
- Investments & Acquisitions
- Acquired bySwedish Orphan Biovitrum
(May 2023)
Products & Services of CTI BioPharma
CTI BioPharma offers a comprehensive portfolio of products and services, including Haematology Treatments, Immunology Treatments, and Specialty Care Medicines.
Medicines for blood-related rare diseases
Innovative therapies for rare immunological conditions
Products for inflammation and genetic diseases
Funding Insights of CTI BioPharma
- Total Rounds 7
- Last Round Post-IPO β $45M
- First Round $30M
(Jan 2010)
- Investors Count 2
All 7 funding rounds of CTI BioPharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2017 | $45M | Post-IPO | β | β | |
| Dec 2013 | $5M | Debt – Venture | β | β | |
| Jan 2011 | $25M | Post-IPO | β | β | β |
| Aug 2010 | $4.6M | Post-IPO | β | β | β |
| Jun 2010 | $1.85M | Post-IPO | β | β | β |
| May 2010 | $21M | Post-IPO | β | β | β |
| Jan 2010 | $30M | Post-IPO | β | β | β |
3 investors in total: 3 institutional.
Investors in CTI BioPharma
CTI BioPharma has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Swedish Orphan Biovitrum, Hercules Capital and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Developer of therapies for rare diseases like Haemophilia, Inflammation, and Genetic diseases | 1988 | sobi.com | Stockholm, Sweden |
Investor details for CTI BioPharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CTI BioPharma
24 people are tracked at CTI BioPharma (9 in leadership, 4 in board & advisors, 11 in team); the tracked headcount is 25.
| Name | Role | Group |
|---|---|---|
Adam R. Craig | President, CEO & Interim Chief Medical Officer | Leadership |
Derald Lo | Vice President Human Resources | Leadership |
Tom Blackwell | Vice President, Information Technology | Leadership |
Connie Providoshin | Regional Business Director | Leadership |
Joe Mansfield | VP US Sales And Sales Operations | Leadership |
William Born | Senior Director Strategic Pricing And Contracting | Leadership |
Wendy Wilson | Associate Director Medical Affairs | Leadership |
Mary Beth Lanza | Senior Director Learning And Development | Leadership |
Allison Hylton | Senior Corporate Controller/senior Director | Leadership |
Michael A. Metzger | Director | Board & advisors |
David Parkinson | Director | Board & advisors |
Matthew D. Perry | Director | Board & advisors |
Reed V. Tuckson | Director | Board & advisors |
James K. Fong | SVP, Commercial Operations | Team |
Lisa Maggio | Sr Medical Science Liaison | Team |
Michael Spinek | Key Account Manager | Team |
Brent Satterlee | Senior Stock Plan Manager | Team |
Tina Bush | Key Account Manager | Team |
Bill Foxx | Key Account Manager | Team |
Joanna Thompson | Senior Medical Science Liaison | Team |
4 more people are available in the full profile.
Complete people profiles for CTI BioPharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CTI BioPharma
CTI BioPharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Zhejiang Novus Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Generic drugs, APIs, and dietary supplements are developed and manufactured. | novuspharma.com | Shaoxing, China | 2015 | Jun 2003 | $192M |
Complete acquisition details for CTI BioPharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of CTI BioPharma
6 dated milestones of CTI BioPharma across 32 years, from founding to its latest funding, stage changes and deals.
- Founded CTI BioPharma is founded.
- Acquisition Acquires Zhejiang Novus Pharmaceuticals.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $30.0M.
- Funding Latest funding round, Post-IPO, of $45.0M.
- Exit Acquired by Swedish Orphan Biovitrum.
Competitors of CTI BioPharma
CTI BioPharma has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of CTI BioPharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CTI BioPharma
Websites that share an audience with CTI BioPharma (ctibiopharma.com).
Websites whose visitors overlap most with CTI BioPharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cytokinetics.com | 100% | 25.3K | #1,072,700 | View details | |
| curis.com | 100% | 4.8K | #3,916,131 | View details | |
celsion.com | celsion.com | 100% | #7,059,744 | β | |
| celgene.com | 100% | View details | |||
| wirb.com | 61% | View details | |||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 6 similar websites and full traffic analytics for CTI BioPharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as CTI BioPharma (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cti Biopharma
Complete news archive for CTI BioPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CTI BioPharma
CTI BioPharma was founded in 1991 and raised its 1st funding round 19 years after it was founded.
CTI BioPharma is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
CTI BioPharma has 25 employees.
Developer of targeted small molecule therapeutics for blood cancer. Their flagship product Pixantrone was granted conditional marketing approval in the EU, as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphomas. Other drugs in the pipeline are Pacritinib (myelofibrosis and relapsed acute myeloid leukemia), Tosedostat (relapsed acute myeloid leukemia and myelodysplastic syndrome), and Paclitaxel poliglumex (ovarian cancer).
CTI BioPharma's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
CTI BioPharma offers Haematology Treatments, Immunology Treatments, and Specialty Care Medicines.
CTI BioPharma has made 1 acquisition, including Zhejiang Novus Pharmaceuticals.
CTI BioPharma has 3 investors. Key investors include Swedish Orphan Biovitrum, Hercules Capital, and Orbimed.
CTI BioPharma operates through Cti Biopharma Corp.
Yes. CTI BioPharma was acquired by Swedish Orphan Biovitrum in May 2023.

